Literature DB >> 9876591

Extension of the International Conference on Harmonization Tripartite Guideline for Stability Testing of New Drug Substances and Products to countries of climatic zones III and IV.

W Grimm1.   

Abstract

The International Conference on Harmonization (ICH) Tripartite Guideline "Stability Testing of New Drug Substances and Products" sets out the stability testing requirements for a registration application within the three areas of the European Union, Japan, and the United States. These areas are assigned to climatic zone II with the storage condition of 25 degrees C/60% RH. This paper describes the adjustments that are necessary to extend the guideline to countries of climatic zones III and IV. At first storage conditions were derived with 30 degrees C/35% RH for climatic zone III and 30 degrees C/70% RH for climatic zone IV. Both conditions contain a margin of safety compared to calculated and measured data in warehouses. Furthermore, they cover the extreme temperatures above 30 and 40 degrees C which may arise in these climatic zones. Six months at 40 degrees C/75% RH was fixed as storage condition for accelerated testing to assess organoleptic and physicochemical test criteria and to make predictions for chemical stability. The predictive factor is 3.3 for 30 degrees C (6 months at 40 degrees C corresponds to 20 months at 30 degrees C). Extreme temperatures which may arise during shipment are covered by the results of stress investigations (e.g., 3 months at 50 degrees C). The next adjustment is necessary for the selection of the packaging containers. They must reflect the requirements for solid, semisolid, and liquid dosage forms caused by the two storage conditions. In the evaluation the temperature difference of 10 degrees C (40-30 degrees C) instead of 15 degrees C has to be considered, which limits the preliminary shelf lives in critical cases to 18 months instead of 24 months. Finally, statement/labeling must reflect the storage conditions. All of the other basic principles for the drug substances and drug products, such as selection and number of batches, test criteria, test procedures, specifications, testing frequency, and storage period can be applied without any change.

Entities:  

Mesh:

Year:  1998        PMID: 9876591     DOI: 10.3109/03639049809085626

Source DB:  PubMed          Journal:  Drug Dev Ind Pharm        ISSN: 0363-9045            Impact factor:   3.225


  9 in total

1.  Eudragit S-100 entrapped chitosan microspheres of valdecoxib for colon cancer.

Authors:  Naveen K Thakral; Alok R Ray; Dipak K Majumdar
Journal:  J Mater Sci Mater Med       Date:  2010-06-10       Impact factor: 3.896

2.  A new strategy to stabilize oxytocin in aqueous solutions: I. The effects of divalent metal ions and citrate buffer.

Authors:  Christina Avanti; Jean-Pierre Amorij; Dewi Setyaningsih; Andrea Hawe; Wim Jiskoot; Jan Visser; Alexej Kedrov; Arnold J M Driessen; Wouter L J Hinrichs; Henderik W Frijlink
Journal:  AAPS J       Date:  2011-03-30       Impact factor: 4.009

3.  Benchmarking the Solubility Enhancement and Storage Stability of Amorphous Drug-Polyelectrolyte Nanoplex against Co-Amorphous Formulation of the Same Drug.

Authors:  Li Ming Lim; Jin-Won Park; Kunn Hadinoto
Journal:  Pharmaceutics       Date:  2022-05-02       Impact factor: 6.525

4.  The initial pharmaceutical development of an artesunate/amodiaquine oral formulation for the treatment of malaria: a public-private partnership.

Authors:  Catherine Lacaze; Tina Kauss; Jean-René Kiechel; Antonella Caminiti; Fawaz Fawaz; Laurent Terrassin; Sylvie Cuart; Luc Grislain; Visweswaran Navaratnam; Bellabes Ghezzoul; Karen Gaudin; Nick J White; Piero L Olliaro; Pascal Millet
Journal:  Malar J       Date:  2011-05-23       Impact factor: 2.979

5.  A new strategy for taste masking of azithromycin antibiotic: development, characterization, and evaluation of azithromycin titanium nanohybrid for masking of bitter taste using physisorption and panel testing studies.

Authors:  Fazli Amin; Shahzeb Khan; Syed Muhammad Hassan Shah; Haroon Rahim; Zahid Hussain; Muhammad Sohail; Riaz Ullah; Mansour S Alsaid; Abdelaaty A Shahat
Journal:  Drug Des Devel Ther       Date:  2018-11-08       Impact factor: 4.162

6.  Actual versus recommended storage temperatures of oral anticancer medicines at patients' homes.

Authors:  N D Vlieland; Bjf van den Bemt; D A van Riet-Nales; M L Bouvy; Acg Egberts; H Gardarsdottir
Journal:  J Oncol Pharm Pract       Date:  2017-11-29       Impact factor: 1.809

7.  Formulation and characterization of ketoprofen liquisolid compacts by Box-Behnken design.

Authors:  G Vijayaranga Vittal; R Deveswaran; S Bharath; Bv Basavaraj; V Madhavan
Journal:  Int J Pharm Investig       Date:  2012-07

8.  Accelerated stability studies of Sufoofe Sailan: A Unani formulation.

Authors:  Seema Rani; Khaleequr Rahman; Peerzada Mohammad Younis
Journal:  Ayu       Date:  2015 Jan-Mar

9.  Preparation and Evaluation of Polymer-Based Ultrasound Gel and Its Application in Ultrasonography.

Authors:  Sadia Afzal; Muhammad Zahid; Zulfiqar Ahmad Rehan; H M Fayzan Shakir; Hamza Javed; Meshari M H Aljohani; Syed Khalid Mustafa; Maqsood Ahmad; Montaser M Hassan
Journal:  Gels       Date:  2022-01-06
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.